Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation

Table 2 Clinical data of prognostic relevant immune modulation by hepatitis B hyperimmunoglobulin in recipients of hepatitis B virus-positive liver allografts

Ref.	HBV characteristics donor/recipient	Antiviral prophylaxis	Impact of HBIg on outcome
Brock et al[94]	HBc+/HBsAg- (n = 958)	HBIg alone: n = 61	70% reduction in risk of mortality by HBIg prophylaxis;
		HBIg + Lam: n = 66	(HR = 0.29, 95%CI: 0.10-0.86, P = 0.026)
		Lam alone: n = 116
		None: n = 509
		Missing data: n = 206
Li et al[112]	HBsAg+/ HBsAg- (n = 63)	With HBIg: n = 17	HBIg independently associated with superior
	HBsAg+/HBsAg+ (n = 15)	Without HBIg: n = 61	posttransplant graft survival;
		With Lam: n = 14	(HR = 0.23, 95%CI: 0.06-0.81) and patient survival
		Without Lam: n = 64	(HR = 0.16, 95%CI: 0.04-0.759)

HBV: Hepatitis B virus; HBIg: Hepatitis B hyperimmunoglobulin; HBc+: Hepatitis B core +; HBsAg: Hepatitis B surface antigen.